December, 23rd, 2016

Nyken is a biopharmaceutical company engaged in the development of heat shock factor 1 (HSF1) activating drugs to treat proteostasis-related diseases such as atrial fibrillation, acute kidney injury and several CNS pathologies. Nyken’s intellectual property and patent portfolio on HSF1 activating drugs has been acquired by Chaperone Pharma, a Dutch biopharmaceutical company. For more information, please contact

Nyken Therapeutics, Groningen, The Netherlands